Work

88P Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application

Year: 2024

Type: article

Abstract: Results: Of the patients with irAEs, 26% (31/116) needed inpatient treatment.Hospitalization was associated with severe (grade III to IV) toxicities (p<0.001).The mOS of patients hospitalized due to an irAE was 12.9 months, while that of outpatients with irAEs was 26.9 months (p¼0.006).The mOS was especially poor if hospital stay exceeded 6 days (7.0 months vs. 19.1 months, p¼0.015).Systemic glucocorticoid therapy was administered to 90.3% of hospitalized and 35.3% of non-hospitalized patients (p<0.05).At disease progression after an irAE, palliative care instead of active oncological therapies was more often provided for hospitalized patients (35.4% vs. 17.6%, p¼0.041).At the initiation of salvage systemic therapy after an irAE, hospitalized patients tended to be in poorer physical condition than outpatients (WHO performance status >2 in 35.7% vs. 14.6% of patients, p¼0.089).Conclusions: Hospital admission due to an irAE appeared to significantly deteriorate the survival of ICI treated metastatic cancer patients.This may be attributed to decreased physical fitness due to long admissions and high-dose, long-term glucocorticoid treatments of severe irAEs.Early rehabilitation and effective tapering of corticosteroid, if possible, should be provided for patients hospitalized due to an irAE.Legal entity responsible for the study: Aino Rönkä.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100831

Authors: M. Csenar, J. Schroer, M. Goldkuhle, L. Moja, N. Skoetz

Institutions: University of Cologne, University Hospital Cologne, World Health Organization

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170